OR WAIT null SECS
Clinical trials disrupted by COVID-19 are expected to resume at a much slower rate than originally anticipated, as more nations are re-enforcing lockdown due to a globally rising number of COVID-19 cases, says GlobalData.
Priya Nair, Trials Intelligence Analyst at GlobalData, commented, “The general trend shows a gradual increase in the overall percentage of trials for each trial status*, the biggest of which has been seen in trials that are ongoing and recruiting and those that are ongoing but not recruiting. Between August 17th and September 21st, ongoing and recruiting trials decreased from 84.7% to 82.2%, while completed trials increased from 4.5% to 6.4%.”
There is also an overall steady increase of trials resuming activity. The U.S. has the highest number of resumed trials at 70.6%, followed by France at 7.6%, the UK and Spain at 7%.
* Completed; Ongoing, not recruiting; Ongoing, recruiting; Planned
For more of their findings, click here.